| May 12,
2006
BioMimetic Therapeutics,
Inc. Announces Pricing of Initial
Public Offering
Franklin, Tenn. – May 12, 2006
- BioMimetic Therapeutics, Inc. (NASDAQ:
BMTI) announced today that it has
priced its initial public offering
of 4.6 million shares of its common
stock at $8.00 per share.
The shares will commence trading
May 12, 2006, on the NASDAQ National
Market under the symbol BMTI. BioMimetic
Therapeutics, Inc. has granted the
underwriters a 30-day option to purchase
an additional 690,000 shares of its
common stock to cover over-allotments,
if any. Deutsche Bank Securities Inc.
will be acting as the sole book-running
manager of this offering, Pacific
Growth Equities, LLC will be acting
as the co-lead manager and First Albany
Capital, Inc. and AG Edwards &
Sons, Inc will be co-managers. Shares
are being offered only by prospectus.
Copies of the prospectus may be obtained
from Deutsche Bank Securities Inc.
at 60 Wall Street, New York, New York
10005, (212) 250-2500.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing
and commercializing bio-active drug-device
combination products for the healing
of musculoskeletal injuries and disease,
including periodontal, orthopedic,
spine and sports injury applications.
BioMimetic received marketing approval
from the FDA for its first product
as a grafting material for bone and
periodontal regeneration following
completion of human clinical trials,
which demonstrated the safety and
efficacy of its platform technology
in this indication. The Company's
product and product candidates all
combine recombinant protein therapeutics
with tissue specific scaffolds to
actively stimulate tissue healing
and regeneration.
A registration statement relating
to these securities was declared effective
by the Securities and Exchange Commission
on May 10, 2006. This announcement
shall not constitute an offer to sell
or the solicitation of an offer to
buy, nor shall there be any sale of
these securities in any state or jurisdiction
in which such offer, solicitation,
or sale would be unlawful prior to
registration or qualification under
the securities laws of any such state
or jurisdiction.
Forward-looking Statements
This press release contains "forward-looking
statements" within the meaning
of the Private Securities Litigation
Reform Act of 1995. These forward-looking
statements are based on the current
intent and expectations of the management
of BioMimetic Therapeutics, Inc. These
statements are not guarantees of future
performance and involve risks and
uncertainties that are difficult to
predict. BioMimetic's actual results
and the timing and outcome of events
may differ materially from those expressed
in or implied by the forward-looking
statements because of risks associated
with our unproven preclinical and
clinical development activities, regulatory
oversight, intellectual property claims,
litigation and other risks. Except
as required by law, BioMimetic undertakes
no obligation to update any forward-looking
or other statements in this press
release, whether as a result of new
information, future events or otherwise.
For further information, visit www.biomimetics.com
or contact Kearstin Patterson, manager
corporate communications, at 615-236-4419.
|
